Diagnosis and treatment of cutaneous leishmaniasis

References

• Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect. Dis.5, 763–774 (2005).
   PubMed Web of Science ®Google Scholar
• Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet366, 1561–1577 (2006).
   Google Scholar
• Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol.5, 873–882 (2007).
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect. Dis.7, 581–596 (2007).
   PubMed Web of Science ®Google Scholar
• Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis.3, 87–98 (2003).
   PubMed Web of Science ®Google Scholar
• Puig L, Pradinaud R. Leishmania and HIV coinfection: dermatological manifestations. Ann. Trop. Med. Parasitol.97(Suppl. 1), S107–S114 (2002).
   Google Scholar
• DesjeuxP. Leishmaniasis. Nat. Rev. Microbiol.2, 692 (2004).
   PubMedGoogle Scholar
• Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann. Trop. Med. Parasitol.97(Suppl. 1), 29–45 (2003).
   PubMed Web of Science ®Google Scholar
• Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin. Microbiol. Rev.19, 111–126 (2006).
   PubMed Web of Science ®Google Scholar
• Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J. Antimicrob. Chemother.53, 158–166 (2004).
   PubMedGoogle Scholar
• Lawn SD, Whetham J, Chiodini PL et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM97, 781–788 (2004).
   PubMed Web of Science ®Google Scholar
• Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M. Cutaneous leishmaniasis: an increasing threat for travellers. Clin. Microbiol. Infect.11, 343–346 (2005).
   PubMedGoogle Scholar
• Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin. Infect. Dis.39, 1674–1680 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. Update: cutaneous leishmaniasis in U.S. military personnel – Southwest/Central Asia, 2002–2004. MMWR Morb. Mortal. Wkly Rep.53, 264–265 (2004).
   PubMedGoogle Scholar
• Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin. Microbiol. Rev.14, 659–688 (2001).
   PubMed Web of Science ®Google Scholar
• Killick-Kendrick R. The biology and control of phlebotomine sandflies. Clin. Dermatol.17, 279–289 (1999).
   PubMed Web of Science ®Google Scholar
• Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv. Parasitol.59, 1–75 (2005).
   PubMedGoogle Scholar
• Weigel MM, Armijos RX, Zurita C, Racines J, Reddy A, Mosquera J. Nutritional status and cutaneous leishmaniasis in rural Ecuadorian children. J. Trop. Pediatr.41, 22–28 (1995).
   PubMedGoogle Scholar
• Yadon ZE, Rodrigues LC, Davies CR, Quigley MA. Indoor and peridomestic transmission of American cutaneous leishmaniasis in northwestern Argentina: a retrospective case–control study. Am. J. Trop. Med. Hyg.68, 519–526 (2003).
   PubMed Web of Science ®Google Scholar
• Alexander B, Maroli M. Control of phlebotomine sandflies. Med. Vet. Entomol.17, 1–18 (2003).
   PubMed Web of Science ®Google Scholar
• Peters W, Killick-Kendrick R. The leishmaniases in biology and medicine. In: Clinical Aspects and Control (Volume 2). Academic Press, London, UK (1987).
   Google Scholar
• Turetz ML, Machado PR, Ko AI et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J. Infect. Dis.186, 1829–1834 (2002).
   PubMed Web of Science ®Google Scholar
• Barral A, Guerreiro J, Bomfim G, Correia D, Barral-Netto M, Carvalho EM. Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am. J. Trop. Med. Hyg.53, 256–259 (1995).
   PubMedGoogle Scholar
• Reithinger R, Aadil K, Kolaczinski J, Mohsen M, Hami S. Social impact of leishmaniasis, Afghanistan. Emerging Infect. Dis.11, 634–636 (2005).
   PubMed Web of Science ®Google Scholar
• Kharfi M, Fazaa B, Chaker E, Kamoun MR. Mucosal localization of leishmaniasis in Tunisia: 5 cases. Ann. Dermatol. Venereol.130, 27–30 (2003).
   PubMed Web of Science ®Google Scholar
• Morsy TA, Khalil NM, Salama MM, Hamdi KN, Shamrany YA, Abdalla KF. Mucosal leishmaniasis caused by Leishmania tropica in Saudi Arabia. J. Egypt Soc. Parasitol.25, 73–79 (1995).
   PubMedGoogle Scholar
• Aliaga L, Cobo F, Mediavilla JD et al. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Balt.)82, 147–158 (2003).
   PubMed Web of Science ®Google Scholar
• Marsden PD. Mucosal leishmaniasis (‘espundia’ Escomel, 1911). Trans. R. Soc. Trop. Med. Hyg.80, 859–876 (1986).
   PubMed Web of Science ®Google Scholar
• Boaventura VS, Cafe V, Costa J et al. Concomitant early mucosal and cutaneous leishmaniasis in Brazil. Am. J. Trop. Med. Hyg.75, 267–269 (2006).
   PubMedGoogle Scholar
• Walton BC, Chinel LV, Eguia OE. Onset of Espundia after many years of occult infection with Leishmania braziliensis. Am. J. Trop. Med. Hyg.22, 696–698 (1973).
   PubMed Web of Science ®Google Scholar
• David C, Dimier-David L, Vargas F, Torrez M, Dedet JP. Fifteen years of cutaneous and mucocutaneous leishmaniasis in Bolivia: a retrospective study. Trans. R. Soc. Trop. Med. Hyg.87, 7–9 (1993).
   PubMedGoogle Scholar
• Escobar MA, Martinez F, Scott Smith D, Palma GI. American cutaneous and mucocutaneous leishmaniasis (tegumentary): a diagnostic challenge. Trop. Doct.22, 69–78 (1992).
   PubMedGoogle Scholar
• Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J. Clin. Microbiol.45, 21–25 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia L, Kindt A, Bermudez H et al. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J. Clin. Microbiol.42, 2294–2297 (2004).
   PubMed Web of Science ®Google Scholar
• De Doncker S, Hutse V, Abdellati S et al. A new PCR-ELISA for diagnosis of visceral leishmaniasis in blood of HIV-negative subjects. Trans. R. Soc. Trop. Med. Hyg.99, 25–31 (2005).
   PubMedGoogle Scholar
• Espy MJ, Uhl JR, Sloan LM et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin. Microbiol. Rev.19, 165–256 (2006).
   PubMed Web of Science ®Google Scholar
• Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J. Clin. Microbiol.42, 5249–5255 (2004).
   PubMed Web of Science ®Google Scholar
• van der Meide WF, Schoone GJ, Faber WR et al. Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples. J. Clin. Microbiol.43, 5560–5566 (2005).
   PubMedGoogle Scholar
• Garcia AL, Kindt A, Quispe-Tintaya KW et al. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infect. Genet. Evol.5, 109–116 (2005).
   PubMedGoogle Scholar
• Schubach A, Haddad F, Oliveira-Neto MP et al. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J. Infect. Dis.178, 911–914 (1998).
   PubMedGoogle Scholar
• Vergel C, Palacios R, Cadena H et al. Evidence for Leishmania (Viannia) parasites in the skin and blood of patients before and after treatment. J. Infect. Dis.194, 503–511 (2006).
   PubMedGoogle Scholar
• van der Meide W, Guerra J, Schoone G et al. Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites. J. Clin. Microbiol.46, 73–78 (2008).
   PubMed Web of Science ®Google Scholar
• Ramirez JR, Agudelo S, Muskus C et al. Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis. J. Clin. Microbiol.38, 3768–3773 (2000).
   PubMed Web of Science ®Google Scholar
• Weigle KA, Labrada LA, Lozano C, Santrich C, Barker DC. PCR-Based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). J. Clin. Microbiol.40, 601–606 (2002).
   PubMed Web of Science ®Google Scholar
• Strauss-Ayali D, Jaffe CL, Burshtain O, Gonen L, Baneth G. Polymerase chain reaction using noninvasively obtained samples, for the detection of Leishmania infantum DNA in dogs. J. Infect. Dis.189, 1729–1733 (2004).
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Hashiguchi Y, Gomez EA et al. Comparison of PCR results using scrape/exudate, syringe-sucked fluid and biopsy samples for diagnosis of cutaneous leishmaniasis in Ecuador. Trans. R. Soc. Trop. Med. Hyg.93, 606–607 (1999).
   PubMed Web of Science ®Google Scholar
• Bensoussan E, Nasereddin A, Jonas F, Schnur LF, Jaffe CL. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J. Clin. Microbiol.44, 1435–1439 (2006).
   PubMed Web of Science ®Google Scholar
• Chappuis F, Rijal S, Soto A, Menten J, Boelaert M. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. Br. Med. J.333, 723 (2006).
   PubMed Web of Science ®Google Scholar
• Kar K. Serodiagnosis of leishmaniasis. Crit. Rev. Microbiol.21, 123–152 (1995).
   PubMed Web of Science ®Google Scholar
• Montoya Y, Leon C, Talledo M et al. Recombinant antigens for specific and sensitive serodiagnosis of Latin American tegumentary leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.91, 674–676 (1997).
   PubMedGoogle Scholar
• Vexenat Ade C, Santana JM, Teixeira AR. Cross-reactivity of antibodies in human infections by the kinetoplastid protozoa Trypanosoma cruzi, Leishmania chagasi and Leishmania (Viannia) braziliensis. Rev. Inst. Med. Trop. Sao Paulo38, 177–185 (1996).
   PubMedGoogle Scholar
• Weigle KA, de Davalos M, Heredia P, Molineros R, Saravia NG, D’Alessandro A. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am. J. Trop. Med. Hyg.36, 489–496 (1987).
   PubMed Web of Science ®Google Scholar
• Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am. J. Trop. Med. Hyg.44, 260–271 (1991).
   PubMed Web of Science ®Google Scholar
• Fagundes A, Marzochi MC, Perez M et al. Skin reactivity to thimerosal and phenol-preserved Montenegro antigen in Brazil. Acta Trop.101, 25–30 (2007).
   PubMedGoogle Scholar
• Convit J. Leishmaniasis: immunological and clinical aspects and vaccines in Venezuela. Clin. Dermatol.14, 479–487 (1996).
   PubMedGoogle Scholar
• Roussel M, Nacher M, Fremont G et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol.100, 307–314 (2006).
   PubMed Web of Science ®Google Scholar
• Lai A, Fat EJ, Vrede MA, Soetosenojo RM, Lai A, Fat RF. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int. J. Dermatol.41, 796–800 (2002).
   PubMed Web of Science ®Google Scholar
• Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis.24, 684–703 (1997).
   PubMed Web of Science ®Google Scholar
• Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des.8, 319–342 (2002).
   PubMed Web of Science ®Google Scholar
• Franke ED, Wignall FS, Cruz ME et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann. Intern. Med.113, 934–940 (1990).
   PubMed Web of Science ®Google Scholar
• Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am. J. Trop. Med. Hyg.77, 266–274 (2007).
   PubMed Web of Science ®Google Scholar
• Reithinger R, Mohsen M, Wahid M et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin. Infect. Dis.40, 1148–1155 (2005).
   PubMed Web of Science ®Google Scholar
• Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am. J. Trop. Med. Hyg.65, 466–470 (2001).
   PubMed Web of Science ®Google Scholar
• Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. Am. J. Trop. Med. Hyg.64, 187–193 (2001).
   PubMed Web of Science ®Google Scholar
• Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-g in treating cutaneous leishmaniasis in Guatemala. Clin. Infect. Dis.18, 381–384 (1994).
   PubMed Web of Science ®Google Scholar
• Wortmann G, Miller RS, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin. Infect. Dis.35, 261–267 (2002).
   PubMed Web of Science ®Google Scholar
• Franke ED, Llanos-Cuentas A, Echevarria J et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am. J. Trop. Med. Hyg.51, 77–82 (1994).
   PubMed Web of Science ®Google Scholar
• Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents13, 243–248 (2000).
   PubMed Web of Science ®Google Scholar
• Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis.16, 417–425 (1993).
   PubMed Web of Science ®Google Scholar
• Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg.72, 133–137 (2005).
   PubMed Web of Science ®Google Scholar
• Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am. J. Trop. Med. Hyg.50, 107–111 (1994).
   PubMed Web of Science ®Google Scholar
• de Paula CD, Sampaio JH, Cardoso DR, Sampaio RN. [A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20 mg SbV/day for 20 days to treat cutaneous leishmaniasis]. Rev. Soc. Bras. Med. Trop.36, 365–371 (2003).
   PubMedGoogle Scholar
• Nacher M, Carme B, Sainte Marie D et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol.95, 331–336 (2001).
   PubMed Web of Science ®Google Scholar
• Correia D, Macêdo VO, Carvalho EM et al. [Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis]. Rev. Soc. Bras. Med. Trop.29, 447–453 (1996).
   PubMedGoogle Scholar
• Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.88, 695–698 (1994).
   PubMed Web of Science ®Google Scholar
• Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.88, 700–703 (1994).
   PubMed Web of Science ®Google Scholar
• Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans. R. Soc. Trop. Med. Hyg.88, 334–339 (1994).
   PubMed Web of Science ®Google Scholar
• Romero GA, Lessa HA, Orge MG, Macêdo VO, Marsden PD. [Treatment of mucosal leishmaniasis with aminosidine sulfate: results of two year follow-up]. Rev. Soc. Bras. Med. Trop.31, 511–516 (1998).
   PubMedGoogle Scholar
• Soto J, Hernandez N, Mejia H, Grogl M, Berman J. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin. Infect. Dis.20, 47–51 (1995).
   PubMed Web of Science ®Google Scholar
• Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin. Infect. Dis.26, 56–58 (1998).
   PubMed Web of Science ®Google Scholar
• Arevalo I, Ward B, Miller R et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis.33, 1847–1851 (2001).
   PubMed Web of Science ®Google Scholar
• Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis.40, 1395–1403 (2005).
   PubMed Web of Science ®Google Scholar
• Arevalo I, Tulliano G, Quispe A et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin. Infect. Dis.44, 1549–1554 (2007).
   PubMed Web of Science ®Google Scholar
• Firooz A, Khamesipour A, Ghoorchi MH et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch. Dermatol.142, 1575–1579 (2006).
   PubMed Web of Science ®Google Scholar
• Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N. Engl. J. Med.346, 891–895 (2002).
   PubMed Web of Science ®Google Scholar
• Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis.165, 528–534 (1992).
   PubMed Web of Science ®Google Scholar
• Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am. J. Trop. Med. Hyg.89, 147–155 (1990).
   Google Scholar
• Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis.33, E57–E61 (2001).
   PubMedGoogle Scholar
• Soto J, Arana BA, Toledo J et al. Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis.38, 1266–1272 (2004).
   PubMed Web of Science ®Google Scholar
• Soto J, Rea J, Balderrama M, Toledo J, Soto P, Berman J. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg.78(2), 210–211 (2008).
   PubMed Web of Science ®Google Scholar
• Soto J, Toledo J, Valda L et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin. Infect. Dis.44, 350–356 (2007).
   PubMed Web of Science ®Google Scholar
• Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (Glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am. J. Trop. Med. Hyg.42, 43–50 (1990).
   PubMed Web of Science ®Google Scholar
• Velasco-Castrejon O, Walton BC, Rivas-Sanchez B et al. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am. J. Trop. Med. Hyg.57, 309–312 (1997).
   PubMed Web of Science ®Google Scholar
• Bailey MS, Green AD, Ellis CJ et al. Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J. R. Army Med. Corps151, 73–80 (2005).
   PubMedGoogle Scholar
• Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg.46, 296–306 (1992).
   PubMed Web of Science ®Google Scholar
• Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol.22, 552–557 (2006).
   PubMed Web of Science ®Google Scholar
• Goodwin LG. Pentostam (sodium stibogluconate); a 50-year personal reminiscence. Trans. R. Soc. Trop. Med. Hyg.89, 339–341 (1995).
   PubMed Web of Science ®Google Scholar
• Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006.Kinetoplastid Biol. Dis.6, 3 (2007).
   PubMedGoogle Scholar